Acute and chronic endothelial dysfunction: Implications for the development of heart failure

Heart Failure Reviews

Volumn 8, Issue 1, 2003, Pages 87-97

  Linke, Axel ^a   Recchia, Fabio ^a   Zhang, Xiaoping ^a   Hintze, Thomas H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

cAMP; Downregulation; eNOS; iNOS; L arginine; Nitric oxide; Oxygen radicals

Indexed keywords

ALLOPURINOL; AMLODIPINE; ANTIOXIDANT; ARGININE; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SPIRONOLACTONE;

CELL FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE MODEL; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; ENDOTHELIUM LESION; EXERCISE; EXERCISE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HUMAN; MEAN ARTERIAL PRESSURE; MOLECULAR DYNAMICS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; TACHYCARDIA;

ACUTE DISEASE; ANIMALS; CARRIER PROTEINS; CHRONIC DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II;

EID: 0037230940     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022151106019     Document Type: Review

References (118)

1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE. The epidemiology of heart failure. Eur Heart J 1997;18:208-225.
2. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998;98:2709-2715.
3. Zelis R, Flaim SF. Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis 1982;24:437-459.
4. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-1596.
5. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-621.
6. Francis GS, Rector TS, Cohn JN. Sequential neurohumoral measurements in patients with congestive heart failure. Am Heart J 1988;116:1464-1468.
7. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
8. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
9. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
10. Cherry PD, Furchgott RF, Zawadzki JV, Jothianandan D. Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci USA 1982;79:2106-2110.
11. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250:H1145-H1149.
12. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012.
13. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996;79:363-380.
14. Schwarz P, Diem R, Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 1995;77:841-848.
15. Ishibashi Y, Shimada T, Murakami Y, Takahashi N, Sakane T, Sugamori T, Ohata S, Inoue S, Ohta Y, Nakamura K, Shimizu H, Katoh H, Hashimoto M. An inhibitor of inducible nitric oxide synthase decrease forearm blood flow in patients with congestive heart failure. J Am Coll Cardiol 2001;38:1470-1476.
16. Habib FM, Springal DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996;347:1151-1155.
17. Haywood GA, Tsao PS, De Leyen HE, Mann MJ, Keeling PJ, Trindade PT, Lewis NP, Byrne CD, Rickenbacher PR, Bishopric NH, Cooke JP, McKenna WJ, Fowler MB. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-1094.
18. Nathan C, Xie QW. Nitric oxide synthases: Roles, tolls, and controls. Cell 1994;78:915-918.
19. Elsner D, Muntze A, Kromer EP, Reigger GAA. Systemic vasoconstriction induced by inhibition of nitric oxide synthesis is attenuated in conscious dogs with heart failure. Cardiovasc Res 1991;25:438-440.
20. Kaiser L, Spickard RC, Oliver NB. Heart failure depresses endothelium-dependent responses in canine femoral artery. Am J Physiol 1989;256:H962-H967.
21. Shen W, Lundborg M, Wang J, Stewart J, Xu X, Ochoa M, Hintze TH. Role of EDRF in the regulation of regional blood flow during exercise. J Appl Physiol 1994;77:165-172.
22. Hintze TH, Wang J, Seyedi N, Wolin M. Myocardial hypertrophy and failure: Association between alterations in the production or release of EDRF/NO and myocardial dysfunction. In: Bevan J, Kaley G, Rubayani G, eds. Flow-Dependent Regulation of Vascular Function. 1995.
23. Larosa G, Forrester C. Coronary B-adrenoreceptor function is modified by the endothelium in heart failure. J Vasc Res 1996;33:62-70.
24. Redfield MM, Aarhus LL, Wright RS, Burnett JC. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation 1993;87:2016-2022.
25. Zhao G, Shen W, Xu X, Ochoa M, Bernstein R. Hintze TH. Selective impairment of vagal-mediated NO dependent coronary vasodilation in conscious dogs after pacing induced heart failure. Circulation 1995;91:2655-2663.
26. Shen W, Wang J, Ochoa M, Xu X, Hintze TH. Role of endothelium-derived relaxing factor in parasympathetic coronary vasodilation following carotid chemoreflex activation in conscious dogs. Am J Physiol 1994;267:H605-613.
27. Zhang X, Recchia F, Bernstein RD, Xu X, Nasjletti Hintze TH. Kinin-mediated coronary nitric oxide production contributes to the therapeutic actions of ACE and NEP inhibitors and amlodipine in the treatment of heart failure. JPET 1999;288:742-751.
28. Sun D, Huang A, Zhao G, Bernstein RD, Forfia P, Xu X, Koller A, Kaley G, Hintze TH. Reduced NO-dependent arteriolar dilation during the development of cardiomyopathy. Am J Physiol 2000;278:H461-H468.
29. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu XB, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in conscious dogs. Circ Res 1998;83:969-979.
30. Tada H, Thompson CI, Recchia FA, Loke KE, Ochoa M, Smith CJ, Shesely EG, Kaley G, Hintze TH. Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in the Langendorff Mouse heart. Circ Res 2000;86:270-278.
31. Recchia FA, Osorio JC, Chandler MP, Xu X, Panchal AR, Lopashuk GD, Hintze TH, Stanley WC. Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. Am J Physiol 2002;282:E197-E206.
32. Smith CJ, Sun D, Hoegler C, Zhao G, Xu X, Kobari Y, Pritchard K, Sessa WC, Hintze TH. Reduced gene expression of vascular nitric oxide synthase and cyclo-oxygenase-1 in heart failure. Circ Res 1996;78:58-64.
33. Zhang X, Tada H, Wang Z, Hintze TH. cAMP signal transduction: A potential compensatory pathway for coronary endothelial nitric oxide production after heart failure. ATVB 2002;22:1273-1278.
34. Wang J, Wolin MS, Hintze TH. Chronic exercise enhances endothelium-mediated dilation of epicardial coronary artery in conscious dogs. Circ Res 1993;73:829-838.
35. Bernstein RD, Ochoa FY, Xu X, Forfia P, Shen W, Thompson CI, Hintze TH. Function and production of nitric oxide in the coronary circulation of the conscious dog during exercise. Circ Res 1996;79:840-848.
36. Zhao G, Zhang X, Xu X, Ochoa M, Hintze TH. Exercise training enhances reflex cholinergic, NO dependent coronary dilation in conscious dogs. Circ Res 1997;80:868-876.
37. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial nitric oxide gene expression. Circ Res 1994;74:349-353.
38. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effect of an angiotensin-converting-enzyme inhibitor, ramapril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:201-202.
39. Zhang X, Xie Y, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors stimulate nitric oxide production to modulate myocardial oxygen consumption. Circulation 1997;95:176-182.
40. Kichuk MR, Seyedi N, X Zhang, Marboe CC, Michler RE, Addonizio LJ, Kaley G, Nasjletti A, Hintze TH. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation. Circulat 1996;94:44-51.
41. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels-an unexpected mechanism of action of a calcium-channel blocking agent. Circulat 1998;97:576-580.
42. Zhang X, Kichuk MR, Mital S, Oz M, Michler RE, Nasjletti A, Kaley G, Hintze TH. Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels from failing human heart. Am J Cardiol 1999;84:27L-33L.
43. Lauf U, LaFata V, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated downregulation of endothelial nitric oxide synthase. J Biol Chem 1997;272:31725-31729.
44. Mital S, X Zhang, G Zhao, Bernstein RD, Smith CJ, Fulton DL, Sessa WC, Liao JK, Hintze TH. Simvastatin upregulates coronary vascular nitric oxide synthase and nitric oxide production in conscious dogs. Am J Physiol 2000;279:H2649-H2657.
45. Mital S, Magneson A, Loke KE, Liao J, Forfia P, Hintze TH. Simvastatin acts synergistically with ACE inhibitors and amlodipine to decrease oxygen consumption in the rat heart. J Cardiovas Pharm 2000;36:248-254.
46. Trochu J-N, Mital S, Xu X, Ochoa M, Liao J, Recchia FA, Hintze TH. Preservation of NO production by stains: A new therapy for the treatment of heart failure. FASEB J 2001;15:A783 (abstract).
47. Fulton D, Gratto JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke T, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by protein kinase Akt. Nature 1999;399:597-601.
48. Dimmler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosporylation. Nature 1999;399:601-605.
49. Anggard E. Nitric oxide: Mediator, murderer, and medicine. Lancet 1994;343:1199-1206.
50. Hirooka Y, Imaizumi T, Tagawa T, Shiramoto M, Endo T, Ando S, Takeshita A. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure. Circulation 1994;90:658-668.
51. Koifman B, Wollman Y, Bogomolny N, Chernichowsky T, Finkelstein A, Peer G, Scherez J, Blum M, Laniado S, Iaina A. Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. J Am Coll Cardiol 1995;26:1251-1256.
52. Kanaya Y, Nakamura M, Kobayashi N, Hiramori K. Effects of L-arginine on lower limb vasodilator reserve and exercise capacity in patients with chronic heart failure. Heart 1999;81:512-517.
53. Watanabe G, Tomiyama H, Doba N. Effects of oral administration of L-arginine on renal function in patients with heart failure. J Hypertens 2000;18:229-234.
54. Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996;93:2135-2141.
55. Hambrecht R, Hilbrich L, Erbs S, Gielen S, Fiehn E, Schoene N, Schuler G. Correction of endothelial dysfunction in chronic heart failure: Additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000;35:706-713.
56. Chin-Dusting JP, Kaye DM, Lefkovits J, Wong J, Bergin P, Jennings GL. Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J Am Coll Cardiol 1996;27:1207-1213.
57. Kubes P, Kanwar S, Niu XF, Gaboury JP. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. FASEB J 1993;7:1293-1299.
58. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-2551.
59. Toutouzas PC, Tousoulis D, Davies GJ. Nitric oxide synthesis in atherosclerosis. Eur Heart J 1998;19:1504-1511.
60. McDonald KK, Zharikov S, Block ER, Kilberg MS. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox". J Biol Chem 1997;272:31213-31216.
61. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998;62:2425-2430.
62. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996;219:598-603.
63. Kaye DM, Ahlers BA, Autelitano DJ, Chin-Dusting JP. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 2000;102:2707-2712.
64. Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP, Cederbaum SD, Ignarro LJ. Arginase activity in endothelial cells: Inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol 1996;271:H1988-H1998.
65. Arnal JF, Munzel T, Venema RC, James NL, Bai CL, Mitch WE, Harrison DG. Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. J Clin Invest 1995;95:2565-2572.
66. Wascher TC, Posch K, Wallner S, Hermetter A, Kostner GM, Graier WF. Vascular effects of L-arginine: Anything beyond a substrate for the NO-synthase? Biochem Biophys Res Commun 1997;234:35-38.
67. Pedrinelli R, Ebel M, Catapano G, Dell'Omo G, Ducci M, Del Chicca M, Clerico A. Pressor, renal and endocrine effects of L-arginine in essential hypertensives. Eur J Clin Pharmacol 1995;48:195-201.
68. Schmidt HH, Warner TD, Ishii K, Sheng H, Murad F. Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science 1992;255:721-723.
69. Giugliano D, Marfella R, Verrazzo G, Acampora R, Coppola L, Cozzolino D, D'Onofrio F. The vascular effects of L-arginine in humans. The role of endogenous insulin. J Clin Invest 1997;99:433-438.
70. Oxygen free radicals and congestive heart failure. Belch JJ, Bridges AB, Scott N, Chopra M. Br Heart J 1991;65:245-248.
71. Elevated breath pentane in heart failure reduced by free radical scavenger. Sobotka PA, Brottman MD, Weitz Z, Birnbaum AJ, Skosey JL, Zarling EJ. Free Radic Biol Med 1993;13:643-647.
72. Oxidative stress and heart failure. Singh N, Dhalla AK, Senevirante C, Singal PK. Mol Cell Biochem 1995;147:77-81.
73. Evidence of oxidative stress in chronic heart failure in humans. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Eur Heart J 1993;14:1493-1498.
74. Increased oxidative stress in patients with congestive heart failure. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN. J Am Coll Cardiol 1998;31:1352-1356.
75. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Hornig B, Arakawa N, Kohler C, Drexler H. Circulation 1998;97:363-368.
76. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: Role of enhanced vascular superoxide production. Circulation 1999;100:292-298.
77. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, Hare JM. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-2411.
78. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 2002;105:2619-2624.
79. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999;85:357-363.
80. Yucel D, Aydogdu S, Cehreli S, Saydam G, Canatan H, Senes M, Cigdem TB, Nebioglu S. Increased oxidative stress in dilated cardiomyopathic heart failure. Clin Chem 1998;44:148-154.
81. Gokce N, Keaney JF Jr., Frei B, Holbrook M, Olesiak M, Zachariah BJ, Leeuwenburgh C, Heinecke JW, Vita JA. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999;99:3234-3240.
82. Ito K, Akita H, Kanazawa K, Yamada S, Terashima M, Matsuda Y, Yokoyama M. Comparison of effects of ascorbic acid on endothelium-dependent vasodilation in patients with chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy versus patients with effort angina pectoris secondary to coronary artery disease. Am J Cardiol 1998;82:762-767.
83. Ellis GR, Anderson RA, Lang D, Blackman DJ, Morris RH, Morris-Thurgood J, McDowell IF, Jackson SK, Lewis MJ, Frenneaux MP. Neutrophil superoxide anion - Generating capacity, endothelial function and oxidative stress in chronic heart failure: Effects of s. J Am Coll Cardiol 2000;36:1474-1482.
84. Erbs S, Mobius-Winkler S, Gielen S, Schoene N, Linke A, Schulze PC, Hambrecht R. Correction of endothelial dysfunction by vitamin C: Different effects in ischemic heart disease and dilative cardiomyopathy. Circulation 2000;102:II-55.
85. Heller R, Munscher-Paulig F, Grabner R, Till U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem 1999;274:8254-8260.
86. Mizutani A, Maki H, Torii Y, Hitomi K, Tsukagoshi N. Ascorbate-dependent enhancement of nitric oxide formation in activated macrophages. Nitric Oxide 1998;2:235-241.
87. Murphy ME, Piper HM, Watanabe H, Sies H. Nitric oxide production by cultured aortic endothelial cells in response to thiol depletion and replenishment. J Biol Chem 1991;266:19378-19383.
88. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992;258:1898-1902.
89. Packer JE, Slater TF, Willson RL. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 1979;278:737-738.
90. Jarasch ED, Grund C, Bruder G, Heid HW, Keenan TW, Franke WW. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 1981;25:67-82.
91. Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: Structure-based mechanism of conversion. Proc Natl Acad Sci USA 2000;97:10723-10728.
92. Bakhtiiarov ZA. [Changes in xanthine oxidase activity in patients with circulatory failure]. Ter Arkh 1989;61:68-69.
93. Doehner W, Rauchhaus M, Florea VG, Sharma R, Bolger AP, Davos CH, Coats AJ, Anker SD. Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance. Am Heart J 2001;141:792-799.
94. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, Mudrick D, Marban E, Kass DA, Hare JM. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002;90:297-304.
95. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
96. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-2706.
97. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-597.
98. Bauersachs J, Heck M, Fraccarollo D, Hildemann SK, Ertl G, Wehling M, Christ M. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39:351-358.
99. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996;93:210-214.
100. Katz SD, Yuen J, Bijou R, LeJemtel TH. Training improves endothelium-dependent vasodilation in resistance vessels of patients with heart failure. J Appl Physiol 1997;82:1488-1492.
101. Hambrecht R, Schulze PC, Gielen S, Linke A, Mobius-Winkler S, Yu J, Kratzsch JJ, Baldauf G, Busse MW, Schubert A, Adams V, Schuler G. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol 2002;39:1175-1181.
102. Hambrecht R, Fiehn E, Yu J, Niebauer J, Weigl C, Hilbrich L, Adams V, Riede U, Schuler G. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol 1997;29:1067-1073.
103. Linke A, Schoene N, Gielen S, Hofer J, Erbs S, Schuler G, Hambrecht R. Endothelial dysfunction in patients with chronic heart failure: Systemic effects of lower-limb exercise training. J Am Coll Cardiol 2001;37:392-397.
104. Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, Schoene N, Schuler G. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA 2000;283:3095-3101.
105. Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, Coats AJ. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: Effects of physical training. Circulation 1996;93:940-952.
106. Kiilavuori K, Toivonen L, Naveri H, Leinonen H. Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability. Eur Heart J 1995;16:490-495.
107. Coats AJ, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L, Solda PL, Davey P, Ormerod O, Forfar C. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992;85:2119-2131.
108. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: Effects on functional capacity, quality of life, and clinical outcome. Circulation 1999;99:1173-1182.
109. Ranjan V, Xiao Z, Diamond SL. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. Am J Physiol 1995;269:H550-H555.
110. Noris M, Morigi M, Donadelli R, Aiello S, Foppolo M, Todeschini M, Orisio S, Remuzzi G, Remuzzi A. Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res 1995;76:536-543.
111. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994;74:349-353.
112. Wang J, Wolin MS, Hintze TH. Chronic exercise enhances endothelium-mediated dilation of epicardial coronary artery in conscious dogs. Circ Res 1993;73:829-838.
113. Woodman CR, Muller JM, Laughlin MH, Price EM. Induction of nitric oxide synthase mRNA in coronary resistance arteries isolated from exercise-trained pigs. Am J Physiol 1997;273:H2575-H2579.
114. Laughlin MH, Pollock JS, Amann JF, Hollis ML, Woodman CR, Price EM. Training induces nonuniform increases in eNOS content along the coronary arterial tree. J Appl Physiol 2001;90:501-510.
115. Boo YC, Sorescu G, Boyd N, Shiojima I, Walsh K, Du J, Jo H. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: Role of protein kinase A. J Biol Chem 2002;277:3388-3396.
116. Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem 1998;273:34724-34729.
117. Posch K, Schmidt K, Graier WF. Selective stimulation of L-arginine uptake contributes to shear stress-induced formation of nitric oxide. Life Sci 1999;64:663-670.
118. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 2000;105:1631-1639.